NAFLD/NASH
INDIGO’s assay kits and services can provide valuable information for your NAFLD/NASH research. Whether you are interested in a single-receptor assay or a full-panel study, we can help you obtain the data you need quickly.
Receptors for NAFLD/NASH Research
Understanding the mechanisms underlying the involvement of nuclear receptors in the pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD) or Non-Alcoholic Steatohepatitis (NASH) may offer targets for the development of new treatments for this liver disease. The most common nuclear receptors used in drug and treatment discovery are ligand-activated nuclear receptors, including peroxisome proliferator-activated receptor alpha (PPARα), pregnane X receptor (PXR), and constitutive androstane receptor (CAR), which were first identified as key regulators of the responses against chemical toxicants. Numerous studies using mouse disease models and human samples have revealed critical roles for these receptors and others, such as PPARβ/δ, PPARγ, farnesoid X receptor (FXR), and liver X receptors (LXR), in maintaining nutrient/energy homeostasis in part through modulation of the gut-liver-adipose axis.
NAFLD is associated with altered nuclear receptor function and perturbations along the gut-liver axis. These perturbations include obesity, abnormal hepatic lipid metabolism, increased inflammation, and insulin resistance. Nuclear receptors are essential to understanding the physiology and pathology of liver diseases like NAFLD/NASH, as they are at the crossroads of metabolism, inflammation, and regeneration. Modulation of nuclear receptors has been shown to reduce hepatic steatosis, inflammation, insulin resistance, fibrosis, and obesity, making them attractive – and effective – therapeutic targets.
Indigo Assays for NAFLD/NASH Research
INDIGO Biosciences offers assays for receptors that are implicated as promising therapeutic targets for NAFLD/NASH: